非小细胞肺癌的抗体药物偶联物：靶点和生物标志物在哪里？

IF 10 1区医学 Q1 ONCOLOGY

Clinical Cancer Research Pub Date : 2025-04-28 DOI:10.1158/1078-0432.ccr-25-0839

Fred R. Hirsch

引用次数: 0

摘要

adc是一种新兴的非小细胞肺癌治疗方法。有些不需要生物标志物，而另一些则需要突变和/或蛋白质表达。新的诊断技术为更好地识别目标和选择患者提供了机会。联合治疗可能会扩大相关患者群体，但可能需要联合生物标志物选择范例。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

查看原文本刊更多论文

Antibody Drug Conjugates in Non-Small Cell Lung Cancer: Where is the Target and the Biomarker?

ADCs are an emerging treatment of NSCLC. Some do not require biomarkers, while others require mutations and/or protein expression. New diagnostic technologies give opportunities for better target identification and selection of patients. Combination therapies might broaden relevant patient populations but might call for combined biomarker selection paradigms.

求助全文

通过发布文献求助，成功后即可免费获取论文全文。去求助

来源期刊

Clinical Cancer Research 医学-肿瘤学

CiteScore

20.10

自引率

1.70%

发文量

1207

审稿时长

2.1 months

期刊介绍： Clinical Cancer Research is a journal focusing on groundbreaking research in cancer, specifically in the areas where the laboratory and the clinic intersect. Our primary interest lies in clinical trials that investigate novel treatments, accompanied by research on pharmacology, molecular alterations, and biomarkers that can predict response or resistance to these treatments. Furthermore, we prioritize laboratory and animal studies that explore new drugs and targeted agents with the potential to advance to clinical trials. We also encourage research on targetable mechanisms of cancer development, progression, and metastasis.